Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through its $3.9 billion ...

Q4 2025 Press Conference Call March 5, 2026 4:00 AM ESTCompany ParticipantsAxel LoberBelén Garijo López - Chair of Executive Board ...

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...

Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent ...

Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...

Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as ​9.8%, hurt by negative currency effects and the loss of ​patent protection for a multiple sclerosis drug.

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...

Did you know neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) is a rare genetic disorder that can cause tumors ...